First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy
暂无分享，去创建一个
R. Greil | M. Ziepert | W. Stevens | D. Šálek | F. d'Amore | M. Loeffler | E. Jantunen | U. Fagerli | S. Leppä | J. Zijlstra | P. Lugtenburg | J. Doorduijn | G. Wulf | J. Walewski | H. Hagberg | P. B. Hansen | L. Truemper | P. Brown | J. Kluin-Nelemans | I. Christiansen | R. Fijnheer | B. Altmann | S. Jyrkkiö | T. Relander | M. Grube | K. Wu | G. Hopfinger | M. Silva | A. Janssens | Maria Gomes da Silva | A. Pezzutto | M. Merup | V. Procházka | M. Schaafsma | E. Weidmann | M. Gelder | E. Neste | H. Demuynck | P. Brown | J. Mariz | A. Hoof | G. Lauritzsen | T. Noesslinger | L. Brandefors | L. Bohmer | M. Jankovska | Helle Toldbod | M. Kooy | P. Brown